The Eversense 365 CGM. [Image courtesy of Senseonics]

Eversense 365 CGM。[图片由Senseonics提供]

Senseonics

Senseonics 公司

(NYSE:SENS) today announced a step toward bringing its 365-day continuous glucose monitor to a new geography.

（纽约证券交易所：SENS）今天宣布，将其365天连续血糖监测仪推向一个新的地理位置。

Our sister site,

我们的姊妹网站，

Drug Delivery Business News

药物输送商业新闻

,

,

reports

报告

today that the company submitted its Eversense 365 system for CE mark.

。

Eversense 365, the world’s first 365-day CGM system, is the only CGM offering a year-long wear time. Market-leading, non-implanted CGMs like Abbott’s and Dexcom’s are worn for around two weeks. For Eversense 365 users, this means no frequent sensor changes and only one insertion and one “Day 1” every year..

Eversense 365是世界上第一个365天CGM系统，是唯一提供一年使用寿命的CGM。市场领先的非植入式CGM（如雅培（Abbott）和德克斯康（Dexcom））可佩戴约两周。对于Eversense 365用户来说，这意味着没有频繁的传感器更换，每年只有一次插入和一次“第一天”。。

Senseonics says its sensor delivers consistent accuracy across one year, with almost zero false alerts from compression lows during the night. It offers the freedom to remove the transmitter device without wasting a sensor or adding a warm-up period. Eversense 365 also has on-body vibration alerts for improved discretion, alerting patients even when their mobile phone is out of sight..

Senseonics表示，其传感器在一年内提供了一致的准确性，夜间几乎没有来自压缩低点的错误警报。它提供了在不浪费传感器或增加预热时间的情况下拆卸变送器设备的自由度。Eversense 365还具有身体振动警报，可提高患者的判断力，即使手机不在视线范围内也能发出警报。。

Get the full story at our sister site, Drug Delivery Business News.

在我们的姊妹网站《药物输送商业新闻》上了解完整情况。